Hormone producing organoids to halt age-related disease

JangoBio claims a scientific breakthrough in developing sustainable stem-cell based organoids for hormone restoration.

Having recently closed a $2m seed round, researchers at JangoBio’s Wisconsin laboratory announced that they have successfully created organoids to emulate the production of ovarian and testicular hormones. They claim their approach has the capacity to regenerate and replace hormone-producing tissues and reverse the natural decline of sex hormones that occurs with age.

“The development of hormone-producing organoids paves the way for use in humans and animals,” said Dr Craig Atwood, CEO. “JangoBio is rapidly moving towards testing of our organoid products in animal models.” [1]


Restoration of circulating hormone concentrations offers the benefits of preventing the symptoms of menopause and male andropause – potentially halting age-related disease and increasing the healthy lifespan of humans and animals.


 

Restoration of circulating hormone concentrations offers the benefits of preventing the symptoms of menopause and male andropause – potentially halting age-related disease and increasing the healthy lifespan of humans and animals. The JangoBio team think that implanted organoids may well be the first cell-based therapies to fully reverse hormonal decline and the associated age-related diseases, claiming that organoid-based hormone therapies are superior to traditional single hormone-based therapies, allowing restoration of all hormones produced by the ovaries and testes.

Beginning with companion animals, treatments will be administered by veterinary clinics throughout North America. The next phase of development will introduce these therapies into human clinical trials.

JangoBio utilises regenerative stem-cell based precision medicine to restore circulating hormone balance required for optimal health and Longevity.

[1] https://bit.ly/39W2YOB

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

COVID-19: Leading clinician calls for focus on the biology of aging

Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%. When it comes to the world of Longevity and...

Global investment consortium slated to back Telocyte into Phase 1

Telomerase therapy ready for human Alzheimer’s trials. “There have been more than 400 registered trials for Alzheimer's and, by global consensus, every single one has...

Longevity 2020: shaping-up nicely

Over 45 confirmed speakers for this 5-day online event and a big thank you for your interest. We're moving fast! Longevity 2020 started just over...

Telomeres on repeat to inhibit inflamm-aging

Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres. Inflammation is a double-edged sword; while it is necessary...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.